スマートな糖尿病診断と治療の進め方

出版社： 中山書店
著者：
発行日： 2011-08-30
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784521733777
電子書籍版： 2011-08-30 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,480 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,480 円(税込)

購入する

商品紹介

糖尿病の病態生理，病型分類など診断にかかわる基礎や，運動・栄養療法，インスリン・経口血糖降下薬を用いた薬物療法など，実際の臨床に必要な治療法について解説する。糖尿病をもつ小児や高齢者，妊婦への診療や，患者教育，緊急時の対応まで幅広い内容がスマートにまとめられており，糖尿病診療に必要な最新の臨床の知識・技がこの一冊で学べる。

目次

  • スマートな糖尿病診断と治療の進め方

    ―目次―

    1章　糖尿病の概念・定義
    2章　糖尿病の病因・病態生理・遺伝
    3章　糖尿病の診断
    4章　糖尿病の病型診断
    5章　二次性糖尿病の診断
    6章　糖尿病の治療総論
    7章　食事・運動療法
    8章　経口血糖降下薬療法による2型糖尿病患者のマネージメント
    9章　GLP-1アナログ・GLP-1受容体作動薬
    10章　インスリン療法
    11章　小児糖尿病、糖尿病妊婦、高齢糖尿病患者の治療
    12章　高血糖緊急症の診断と治療
    13章　シックデイと低血糖
    14章　糖尿病治療における教育

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 糖尿病の概念・定義

P.8 掲載の参考文献
1) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
2) Maruyama T, et al. Insulin intervention in slowly progressive insulin-dependent (type1) diabetes mellitus. J Clin Endocrinol Metab 2008 ; 93 : 2115-21.
 
3) 花房俊昭ほか. 劇症1型糖尿病調査研究委員会報告-疫学調査の解析と診断基準の策定. 糖尿病 2005 ; 48 (Suppl 1) : A1-13.
 
4) Wenzlau JM, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007 ; 104 : 17040-5.
 
5) Crowther CA, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005 ; 352 : 2477-86.
PubMed
・ 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 : 2010.
 
・ 日本糖尿病学会編. 糖尿病専門医研修ガイドブック-日本糖尿病学会専門医取得のための研修必携ガイド. 改訂第4版. 診断と治療社 ; 2009.
 

2章 糖尿病の病因・病態生理・遺伝

P.16 掲載の参考文献
1) Verge CF, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes : Combinatorial Islet Autoantibody Workshop. Diabetes 1998 ; 47 : 1857-66.
PubMed
2) Akerblom HK, et al. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002 ; 115 : 18-29.
PubMed
3) Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus : interplay between enterovirus and host. Nat Rev Endocrinol 2010 ; 6 : 279-89.
PubMed
4) Knip M, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010 ; 363 : 1900-8.
PubMed
5) Kawabata Y, et al. Differential association of HLA with three subtypes of type 1 diabetes : fulminant, slowly progressive and acute-onset. Diabetologia 2009 ; 52 : 2513-21.
PubMed
6) 田中昌一郎ほか. 緩徐進行1型糖尿病 (slowly progressive insulin-dependent diabetes mellitus : SPIDDM) の臨床的特徴-日本糖尿病学会1型糖尿病調査研究委員会緩徐進行1型糖尿病分科会報告 (第一報). 糖尿病 2011 ; 54 : 65-75.
 
7) Hanafusa T, Imagawa A. Fulminant type 1 diabetes : a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 2007 ; 3 : 36-45.
PubMed
8) Endo T, et al. Amylase alpha-2A autoantibodies : novel marker of autoimmune pancreatitis and fulminant type 1 diabetes. Diabetes 2009 ; 58 : 732-7.
 
9) Wenzlau JM, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007 ; 104 : 17040-5.
 
10) Rewers M, et al. Epidemiology of Type I Diabetes (chapter 9). Eisenbarth GS ed. Type 1 Diabetes : Cellular, Molecular & Clinical Immunology. (コロラド大学医学部バーバラ・デービス・センターのホームページ, Online Books & Slides. http://www.barbaradaviscenter.org/)
 
・ Ikegami H, et al. Genetic Basis of Type 1 Diabetes : Similarities and Differences between East and West. Rev Diabet Stud 2008 ; 5 : 64-72.
 
・ 池上博司ほか. 1型糖尿病の体質. 日本体質医学会雑誌 2010 ; 72 : 18-25.
Medical*Online
P.22 掲載の参考文献
1) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
2) 日本糖尿病学会編. 糖尿病治療ガイド 2010. 文光堂 ; 2010.
 
3) 荒木栄一. 2型糖尿病の成因・病態. 花房俊昭編. 最新医学別冊. 新しい診断と治療のABC18. 代謝 2. 糖尿病. 改訂第2版. 最新医学社 ; 2010. pp.36-44.
 
4) 岩本安彦, 門脇 孝監. 渥美義仁ほか編. 生涯教育シリーズ 79. 糖尿病診療 2010. 日医師会誌 2010 ; 139 (特別号 2).
 
5) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010.
 
P.27 掲載の参考文献
1) 厚生労働省. 平成20年国民健康・栄養調査報告. http://www.mhlw.go.jp/bunya/kenkou/eiyou/h20-houkoku.html
 
2) Flegal KM, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010 ; 303 : 235-41.
PubMed
3) 吉池信男ほか. Body Mass Indexに基づく肥満の程度と糖尿病, 高血圧, 高脂血症の危険因子との関連-他施設共同研究による疫学的検討. 肥満研究 2000 ; 6 : 4-17.
 
4) Yoon KH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006 ; 368 : 1681-8.
PubMed
5) Nakagami T, et al. Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia 2003 ; 46 : 1063-70.
PubMed
6) 山根公則ほか. 日本人と在米日系人の生活習慣病-糖尿病, 高脂血症, 動脈硬化. 最新医学 2002 ; 57 (増刊) : 689-98.
 
7) 清野裕. 糖尿病の新しい概念. 最新医学 1995 ; 50 (Suppl) : 639-45.
 
8) DeFronzo RA. Lilly lecture 1987. The triumvirate : beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988 ; 37 : 667-87.
PubMed
9) Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians : a meta-analysis. Acta Diabetol 2003 ; 40 (Suppl 1) : S302-4.
 
10) 後藤由夫. 私の糖尿病50年, 糖尿病の増減. 糖尿病ネットワーク. http://www.dm-net.co.jp/gotoh/43/
 
11) Fujimoto WY, et al. Prevalence of diabetes mellitus and impaired glucose tolerance among secondgeneration Japanese-American men. Diabetes 1987 ; 36 : 721-9.
PubMed
12) Nelson KM, Reiber G, Boyko EJ ; NHANES III. Diet and exercise among adults with type 2 diabetes : findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care 2002 ; 25 : 1722-8.
PubMed
13) Sone H, et al ; Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003 ; 361 : 85.
 
14) Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004 ; 291 : 335-42.
PubMed
15) Sone H, et al ; Japan Diabetes Complications Study (JDCS) Group. Cross-sectional association between BMI, glycemic control and energy intake in Japanese patients with type 2 diabetes. Analysis from the Japan Diabetes Complications Study. Diabetes Res Clin Pract 2007 ; 77 (Suppl 1) : S23-9.
 

3章 糖尿病の診断

P.35 掲載の参考文献
1) 小坂樹徳ほか. 糖尿病の診断に関する委員会報告. 糖尿病 1982 ; 25 : 859-66.
 
2) 葛谷健ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 1999 ; 42 : 385-404.
 
3) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
4) Ito C, et al. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract 2000 ; 50 : 225-30.
PubMed
5) Ito C, et al. Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy. Diabetes Res Clin Pract 2000 ; 49 : 181-6.
PubMed
6) 門脇孝ほか. 糖尿病・糖代謝異常に関する診断基準検討委員会報告-空腹時血糖値の正常域に関する新区分. 糖尿病 2008 ; 51 : 281-3.
 
P.41 掲載の参考文献
1) 植山実ほか. 酵素法によるHbA1c測定の有用性-HbA1c測定の国際標準化にむけて. 糖尿病 2010 ; 53 : 385-9.
 
2) Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement : the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007 ; 30 : 2399-400.
 
P.43 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
4) Sacks DB, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002 ; 48 : 436-72.
PubMed
5) American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004 ; 27 (Suppl 1) : S15-35.
 
6) Kobold U, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997 ; 43 : 1944-51.
PubMed
7) Hoelzel W, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden : a method-comparison study. Clin Chem 2004 ; 50 : 166-74.
PubMed
8) The International Expert Commitee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009 ; 32 : 1327-34.
 
9) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告 糖尿病 2010 ; 53 : 450-67.
 
10) 柏木厚典ほか. HbA1c国際標準化に関するわが国の対応-糖尿病関連検査の標準化に関する委員会報告. 糖尿病 2009 ; 52 : 811-8.
 

4章 糖尿病の病型診断

P.52 掲載の参考文献
1) 花房俊昭ほか. 劇症1型糖尿病調査研究委員会報告-疫学調査の解析と診断基準の策定. 糖尿病 2005 ; 48 (suppl 1) : A1-13.
 
2) 春日明ほか. 糖尿病患者におけるインスリン治療必要性予知のための抗グルタミン酸脱炭酸酵素 (GAD) 65抗体価カットオフの検討. 糖尿病 2000 ; 43 : 935-40.
 
3) Maruyama T, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008 ; 93 : 2115-21.
PubMed
4) Kasuga A, et al. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J Autoimmun 1999 ; 12 : 131-5.
PubMed
5) Turner R, et al. UKPDS 25 : autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997 ; 350 : 1288-93.
 
6) Kawasaki E, et al. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab 2010 ; 95 : 707-13.
PubMed
P.56 掲載の参考文献
1) Kobayashi T, et al. Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type 1 diabetes. Diabetes 1987 ; 36 : 510-7.
PubMed
2) Kobayashi T, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993 ; 16 : 780-8.
PubMed
3) 小林哲郎. ゆるやかに進行するインスリン依存型糖尿病 (slowly progressive IDDM). 医学のあゆみ 1991 ; 156 : 937-41.
Medical*Online
4) Kawabata Y, et al. Differential association of HLA with three subtypes of type 1 diabetes : fulminant, slowly progressive and acute-onset. Diabetologia 2009 ; 52 : 2513-21.
PubMed
5) Nakanishi K, et al. Predictive value of insulin autoantibodies for further progression of beta cell dysfunction in non-insulin-dependent diabetics. Diabetes Res 1988 ; 9 : 105-9.
PubMed
6) Kobayashi T, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes : response to Buzzetti et al. Diabetes Care 2007 ; 30 : e126.
PubMed
7) Kobayashi T, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci 2002 ; 958 : 117-30.
PubMed
8) Kobayashi T, et al. Histopathological changes of the pancreas in islet cell antibodies (ICA) positive subjects before and after the clinical onset of insulin-dependent diabetes mellitus (IDDM). Diabetes 1988 ; 37 : 24A.
 
9) Tanaka S, et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit : a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 2009 ; 58 : 2285-91.
 
10) Nakanishi K, et al. Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus. Am J Gastroenterol 1994 ; 89 : 762-6.
PubMed
11) Shimada A, et al. T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report. Diabetes Care 1999 ; 22 : 615-7.
PubMed
12) Nakanishi K, et al. Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 1995 ; 44 : 1334-9.
PubMed
13) Maruyama T, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008 ; 93 : 2115-21.
PubMed
14) 田中昌一郎ほか. GAD 抗体価低値の緩徐進行1型糖尿病 (SPIDDM) におけるβ細胞機能. 糖尿病 2008 ; 51 (Suppl 1) : S316.
 
15) Kobayashi T, et al. Pathological changes in the pancreas of fulminant type 1 diabetes and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) : Innate immunity in fulminant type 1 diabetes and SPIDDM, Diabetes Metabolism Reserch Reviews 2011 ; in press.
 
16) 秋山大一郎ほか. ナテグリニド投与により急速にインスリン分泌能低下をきたした1型糖尿病の1例. 糖尿病 2006 ; 49 : 563. (抄録)
 
17) 小林哲郎. (教育講演) 緩徐進行1型糖尿病 : slowly progressive insulin-dependent (type1) diabetes mellitus (SPIDDM). 日内会誌 2010 ; 99 : 2252-6.
 
・ Aida K, et al. RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes 2011 ; 60 : 884-9.
PubMed
P.59 掲載の参考文献
1) 花房俊昭ほか. 劇症1型糖尿病調査研究委員会報告-疫学調査の解析と診断基準の策定. 糖尿病 2005 ; 48 (suppl 1) : A1-13.
 
2) Imagawa A, et al. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 2005 ; 48 : 294-300.
PubMed
P.64 掲載の参考文献
1) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
2) 春日明ほか. 糖尿病患者におけるインスリン治療必要性予知のための抗グルタミン酸脱炭酸酵素 (GAD) 65抗体価カットオフの検討. 糖尿病 2000 ; 43 : 935-40.
 
P.68 掲載の参考文献
1) Kitagawa T, et al. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr 1998 ; 37 : 111-5.
PubMed
2) Urakami T, et al. Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res 2007 ; 61 : 141-5.
PubMed
3) 杉原茂孝. 糖尿病の登録・評価・情報提供に関する研究. 厚生労働科学研究費補助金 子ども家庭総合研究事業. 法制化後の小児慢性特定疾患治療研究事業の登録・管理・評価・情報提供に関する研究 (主任研究者 藤本純一郎) 平成20年度総括・分担研究報告書. 2009. pp.130-47.
 
4) Sugihara S, et al. Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan. Clin Pediatr Endocrinol 2005 ; 14 : 65-75.
PubMed
5) Miura N, et al. Genetic factors and clinical significance of acanthosis nigricans in obese Japanese children and adolescents. Acta Paediatr 2006 ; 95 : 170-5.
PubMed
6) Yamazaki H, et al. Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children. Pediatr Int 2003 ; 45 : 701-5.
PubMed
7) Yamada K, Nonaka K. Diabetic ketoacidosis in young obese Japanese men. Diabetes Care 1996 ; 19 : 671.
 
8) Urakami T, et al. Prevalence of components of the metabolic syndrome in schoolchildren with newly diagnosed type 2 diabetes mellitus. Pediatr Diabetes 2009 ; 10 : 508-12.
PubMed
9) Sugihara S, et al. Analysis of weight at birth and at diagnosis of childhood-onset type 2 diabetes mellitus in Japan. Pediatr Diabetes 2008 ; 9 : 285-90.
PubMed
・ Rosenbloom AL, et al. ISPAD Clinical Practice Consensus Guidlines 2006-2007. Type 2 diabetes mellitus in the child and adolescent. Pediatr Diabetes 2008 ; 9 : 512-26.
 
P.76 掲載の参考文献
1) Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev 2008 ; 29 : 254-64.
 
2) Horikawa Y, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997 ; 17 : 384-5.
 
3) Murphy R, et al. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008 ; 4 : 200-13.
PubMed
4) Suzuki S, et al. Molecular basis of neonatal diabates in japanese patients. J Clin Endocrinol Metab 2007 ; 92 : 3979-85.
 
5) Fajans SS, et al. Molecular mechanisms and clinical pathophysiology of maturityonset diabetes of the young. N Engl J Med 2001 ; 345 : 971-80.
 
6) Huang-Doran I, et al. Lipodystrophy : metabolic insights from a rare disorder. J Endocrinol 2010 ; 207 : 245-55.
PubMed
・ Slingerland AS. Monogenic diabetes in children and young adults : Challenges for researcher, clinician and patients. Rev Endocr Metab Disord 2006 ; 7 : 171-85.
 
・ Hattersley A. Molecular genetics goes to the diabetes clinic. Clin Med 2005 ; 5 : 476-81.
 
P.79 掲載の参考文献
1) Murphy R, et al. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008 ; 4 : 200-13.
PubMed
2) 南條輝志男ほか. 我が国における遺伝子異常による糖尿病の現況. 糖尿病 1998 ; 41 (suppl 2) : A29-31.
 
3) 依藤亨. 日本人優性遺伝性糖尿病家系の遺伝子解析-major MODY-Xは存在するのか? ホルモンと臨床 2009 ; 57 : 1047-9.
 
P.82 掲載の参考文献
1) Kahn CR, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976 ; 294 : 739-45.
 
2) Imai J, et al. Eradication of insulin resistance. Lancet 2009 ; 374 : 264.
PubMed
3) Muggeo M, et al. Treatment by plasma exchange of a patient with autoantibodies to the insulin receptor. N Engl J Med 1979 ; 300 : 477-80.
 
4) Yamamoto T, et al. Clinical efficacy of insulin-like growth factor-1 in a patient with autoantibodies to insulin receptors : a case report. Diabetes Res Clin Pract 2000 ; 49 : 65-9.
 
5) 堀江一郎ほか. 異なった治療反応性を呈したSLE合併インスリン受容体異常症B型の2例. 糖尿病 2009 ; 52 : 957-63.
 
6) Coll AP, et al. Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med 2004 ; 350 : 310-1.
PubMed
7) Flier JS, et al. The evolving clinical course of patients with insulin receptor autoantibodies : spontaneous remission or receptor proliferation with hypoglycemia. J Clin Endocrinol Metab 1978 ; 47 : 985-95.
PubMed
8) Boreen T, et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993 ; 262 : 1892-5.
 
9) Jackson S, et al. Helicobacter pylori eradication : novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005 ; 78 : 142-50.
PubMed
P.85 掲載の参考文献
1) Wolfram DJ, Wegener HP. Diabetes mellitus and simple optic atrophy among siblings : report on four case. Mayo Clin Proc 1938 ; 13 : 715-8.
 
2) Karasik A, et al. Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram's syndrome. Diabetes Care 1989 ; 12 : 135-8.
 
3) Barrett TG, et al. Neurodegeneration and diabetes : UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995 ; 346 : 1458-63.
PubMed
4) Inoue H, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998 ; 20 : 143-8.
PubMed
5) Takeda K, et al. WFS1 (Wolfram syndrome 1) gene product : predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 2001 ; 10 : 477-84.
PubMed
6) Ishihara H, et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004 ; 13 : 1159-70.
PubMed
7) Amr S, et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet 2007 ; 81 : 673-83.
 
8) Sandhu MS, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 2007 ; 39 : 951-3.
PubMed

5章 二次性糖尿病の診断

P.93 掲載の参考文献
1) 日本糖尿病学会糖尿病診断基準検討委員会. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
 
2) Ito T, et al. Epidemiological study of pancreatic diabetes in Japan in 2005 : a nationwide study. Pancreas 2010 ; 39 : 829-35.
PubMed
3) Kawabe K, et al. The current managements of pancreatic diabetes in Japan. Clin J Gastroenterol 2009 ; 2 : 1-8.
PubMed
4) 日本消化器病学会編. 慢性膵炎診療ガイドライン. 南江堂 ; 2009.
 
5) 中村光男ほか. 胆・膵疾患の栄養管理. 膵性糖尿病の栄養管理. 胆と膵 1992 ; 13 : 375-80.
 
6) 右田良克ほか. すい性糖尿病の臨床経過-とくに合併する血管障害についての検討. 糖尿病 1994 ; 37 : 901-6.
 
P.100 掲載の参考文献
1) 厚生統計協会編. 国民衛生の動向. 厚生統計協会 ; 2007.
 
2) Custro N, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001 ; 27 : 476-81.
PubMed
3) Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 2003 ; 111 : 463-8.
PubMed
4) Knobler H, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000 ; 75 : 355-9.
PubMed
5) Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes : clinical and pathogenic data. Liver Int 2009 ; 29 (Suppl 2) : 13-25.
 
6) 田中博文ほか. インターフェロン, リバビリン併用再治療前に抗GAD抗体強陽性を示し, 早期インスリン投与にて1型糖尿病発症予防を試みたC型慢性肝炎の1例. 肝臓 2010 ; 51 : 292-9.
 
7) Kwon SY, et al. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 2005 ; 22 : 1530-5.
PubMed
8) Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003 ; 348 : 1625-38.
 
9) Inoue M, et al. Diabetes mellitus and the risk of cancer : results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006 ; 166 : 1871-7.
PubMed
P.108 掲載の参考文献
1) Mauvais-Jarvis F. Estrogen and androgen receptors : regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab 2011 ; 22 : 24-33.
PubMed
2) Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003 ; 88 : 2404-11.
PubMed
3) Salpeter SR, et al. Meta-analysis : effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006 ; 8 : 538-54.
PubMed
4) Ding EL, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes : a systematic review and meta-analysis. JAMA 2006 ; 295 : 1288-99.
PubMed
5) Muller M, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005 ; 90 : 2618-23.
 
6) Bojesen A, et al. Prenatal and postnatal prevalence of Klinefelter syndrome : a national registry study. J Clin Endocrinol Metab 2003 ; 88 : 622-6.
 
・ Om PG. Secondary forms of diabetes. In : Kahn CR, et al. ed. Joslin's Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins ; 2004. pp. 477-92.
 
P.114 掲載の参考文献
1) Bengtsson C, et al. Do antihypertensive drugs precipitate diabetes? BMJ 1984 ; 289 : 1495-7.
PubMed
2) Burris JF. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment. Arch Intern Med 1993 ; 153 : 2085-92.
PubMed
3) Fabris P, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003 ; 18 : 549-58.
PubMed
4) American Diabetes Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 ; 27 : 596-601.
PubMed
5) Stampfer MJ, et al. A prospective study of moderate alcohol drinking and risk of diabetes in women. Am J Epidemiol 1988 ; 128 : 549-58.
PubMed

6章 糖尿病治療総論

P.123 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000 ; 342 : 381-9.
 
3) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
4) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
5) Yamamoto-Honda R, et al. Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J 2008 ; 55 : 913-23.
PubMed
6) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
7) Balkau B, et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004 ; 47 : 2118-28.
PubMed
8) Maruyama T, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008 ; 93 : 2115-21.
PubMed
P.129 掲載の参考文献
1) Kannel WB. Risk factors in hypertension. J Cardiovasc Pharmacol 1989 ; 13 (Suppl 1) : S4-10.
 
2) Iimura O. Insulin resistance and hypertension in Japanese. Hypertens Res 1996 ; 19 (Suppl 1) : S1-8.
 
3) 曽根博仁, 山田信博. 各危険因子の違いからみる (4) 糖尿病. Vascular Medicine 2007 ; 3 : 125-34.
 
4) 日本動脈硬化学会. 動脈硬化性疾患予防ガイドライン 2007年版. 日本動脈硬化学会 ; 2007.
Medical*Online
5) Nakajima Y, et al. Practical dietary calorie management, body weight control and energy expenditure of diabetic patients in short-term hospitalization. J Atheroscler Thromb 2010 ; 17 : 558-67.
PubMed
6) Vijan S, Hayward RA ; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus : background paper for the American College of Physicians. Ann Intern Med 2004 ; 140 : 650-8.
PubMed
7) Keech A, et al ; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 2005 ; 366 : 1849-61.
 
8) ACCORD Study Group, Ginsberg HN, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.
 
9) Oikawa S, et al ; JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism : Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009 ; 206 : 535-9.
PubMed
10) Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 ; 351 : 1755-62.
 
11) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
12) ACCORD Study Group, Cushman WC, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1575-85.
 
13) Turnbull F, et al ; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus : results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 ; 165 : 1410-9.
PubMed
14) Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
PubMed
P.136 掲載の参考文献
1) Kawamori R, et al ; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 ; 373 : 1607-14.
 
2) Yamashiro T, et al. The effect of group-based lifestyle interventions on risk factors and insulin resistance in subjects at risk for metabolic syndrome : the Tabaruzaka Study 1. Diabetes Obes Metab 2010 ; 12 : 790-7.
PubMed
3) 曽根博仁ほか. 大規模臨床試験-二次予防-JDCS. 日本臨牀 2008 ; 66 (Suppl 8) : 642-51.
 
4) Kobayashi T, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 2002 ; 958 : 117-30.
PubMed
5) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
6) Wake N, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes : a 10-year followup of the Kumamoto study. Diabetes Res Clin Pract 2000 ; 48 : 201-10.
PubMed
7) Baba S ; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001 ; 54 : 191-201.
 
8) Makino H, et al. INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007 ; 30 : 1577-8.
 
9) Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, et al. Reduction of microalbuminuria in patients with type 2 diabetes : the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007 ; 30 : 1581-3.
PubMed
10) 後藤由夫ほか. 糖尿病性神経障害に対するエパルレスタット (ONO-2235) の臨床的研究-プラセボ (微量治験薬含有) を対照とした二重盲検群間比較試験. 医学のあゆみ 1990 ; 152 : 405-16.
Medical*Online
11) Tajima N, et al ; Primary Prevention Group of Adult Japanese (MEGA) Study. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes : diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008 ; 199 : 455-62.
PubMed
12) Ogawa H, et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial. JAMA 2008 ; 300 : 2134-41.
PubMed
13) Oikawa S, et al. JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism : Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009 ; 206 : 535-9.
PubMed
14) 野田光彦ほか. 糖尿病の血管合併症のトータルケア-早期診断, そして予防へ. 日本内科学会雑誌 2009 ; 98 : 2231-40.
 

7章 食事・運動療法

P.145 掲載の参考文献
1) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010.
 
2) 日本糖尿病学会編. 糖尿病食事療法のための食品交換表, 第6版. 文光堂 ; 2002.
 
3) 日本糖尿病学会編. 「食品交換表」を用いる糖尿病食事療法指導のてびき. 第2版. 文光堂 ; 2004.
 
4) 日本糖尿病学会編. 糖尿病食事療法のための食品交換表 <活用編> -献立例とその応用. 文光堂 ; 2007.
 
P.151 掲載の参考文献
1) Iwao N, et al. Regional difference in lipolysis caused by a beta-adrenergic agonist as determined by the microdialysis technique. Acta Physiol Scand 1997 ; 161 : 481-7.
PubMed
2) Oshida Y, et al. Long-term mild jogging increases insulin action despite no influence on body mass index or VO2 max. J Appl Physiol 1989 ; 66 : 2206-10.
PubMed
3) Yamanouchi K, et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care 1995 ; 18 : 775-8.
 
4) Kitamura I, et al. Effects of aerobic and resistance exercise training on insulin action in the elderly. Geriatr Gerontol Int 2003 ; 3 : 50-5.
 
5) Nagasawa J, et al. Effect of training and detraining on in vivo insulin sensitivity. Int J Sports Med 1990 ; 11 : 107-10.
PubMed
6) 運動所要量・運動指針の策定検討会. 健康づくりのための運動指針 2006-生活習慣病予防のために. 2006.
 
7) 佐藤祐造. 糖尿病教室. 新興医学出版社 ; 1999, p.104.
 
・ Sato Y, et al. Clinical aspects of physical exercise for diabetes/metabolic syndrome. Diabetes Res Clin Pract 2007 ; 77 (Suppl 1) : S87-91.
 
・ Colberg SR, et al. Exercise and type 2 diabetes : the American College of Sports Medicine and the American Diabetes Association : joint position statement executive summary. Diabetes Care 2010 ; 33 : 2692-6, e147-67.
 
・ 佐藤祐造. 運動療法の実際, 最新医学 別冊 新しい診断と治療のABC 18, 糖尿病, 改訂第2版. 最新医学社 ; 2010. pp.94-102.
 
・ 佐藤祐造ほか. 糖尿病と耐糖能異常. 佐藤祐造ほか編. 特定健診・保健指導に役立つ 健康運動指導マニュアル. 文光堂 ; 2008. pp.156-65.
 
・ 日本糖尿病学会編. 運動療法. 糖尿病治療ガイド 2010. 文光堂 ; 2010. pp.42-4.
 
P.157 掲載の参考文献
1) 大阪市立大学大学院医学研究科発達小児医学教室, 大阪市立大学医学部附属病院栄養部編. 糖尿病のあなたへ かんたんカーボカウント-豊かな食生活のために. 改訂版. 医薬ジャーナル社 ; 2009.
 
2) 大阪市立大学大学院医学研究科発達小児医学教室, 大阪市立大学医学部附属病院栄養部編. 糖尿病患者のためのカーボフラッシュカード. 医薬ジャーナル社 ; 2007.
 
3) Warshaw H, Kulkarni K. Complete Guide to Carb Counting. American Diabetes Association ; 2004.
 

8章 経口血糖降下薬療法による2型糖尿病患者のマネージメント

P.166 掲載の参考文献
1) Zhang CL, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009 ; 325 : 607-10.
PubMed
2) Cooperberg BA, Cryer PE. β-cell-mediated signaling predominates over direct α-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 2009 ; 32 : 2275-80.
 
3) Nagashima K, et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents : pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 2004 ; 66 (Suppl 1) : S75-8.
 
4) Meinert CL, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970 ; 19 (Suppl) : 789-830.
 
5) NAVIGATOR Study Group, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1463-76.
 
P.174 掲載の参考文献
1) 山崎勝也. ビグアナイド薬の使い方. 小林正編. 経口血糖降下薬の選び方と使い方. 南江堂 ; 2007. pp.75-95.
 
2) 薄井勲. チアゾリジン薬の使い方. 小林正編. 経口血糖降下薬の選び方と使い方. 南江堂 ; 2007. pp.97-108.
 
3) 山崎勝也, 戸邉一之. メトホルミンとピオグリタゾン合剤の使い方. 月刊糖尿病 2011 ; 3 : 74-82.
 
・ 河盛隆造編. 見直されたビグアナイド-メトホルミン. 改訂版. フジメディカル出版 ; 2009.
 
・ 門脇孝編. 期待されるチアゾリジン薬. フジメディカル出版 ; 2007.
 
P.182 掲載の参考文献
1) 高田康徳, 大澤春彦. αグルコシダーゼ阻害薬の特徴と使い方. 月刊糖尿病 2009 ; 1 : 56-68.
 
2) IDF. Guideline for Management of Postmeal Glucose 2007. http://www.idf.org/postmeal-glucose-guideline
 
3) 堀川幸男, 武田純. 新しい糖尿病治療薬 2-DPP-4阻害薬と他剤との併用療法. 月刊糖尿病 2011 ; 3 : 52-61.
 
4) 山田祐一郎. インクレチン薬の作用メカニズムとその有用性. Mebio 2009 ; 26 : 44-9.
Medical*Online
5) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010.
 
6) Fujishima M, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan : The Hisayama Study. Diabetes 1996 ; 45 (Suppl 3) : S14-6.
 
7) Hanefeld M, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients : meta-analysis of seven long-term studies. Eur Heart J 2004 ; 25 : 10-6.
PubMed
8) Chiasson JL, et al. Acarbose for prevention of type 2 diabetes mellitus : the STOPNIDDM randomised trial. Lancet 2002 ; 359 : 2072-7.
PubMed
9) Kawamori R, et al. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 ; 373 : 1607-14.
PubMed
P.188 掲載の参考文献
1) Horton ES, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010 ; 33 : 1759-65.
PubMed
2) Iwamoto Y, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes : a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010 ; 12 : 700-8.
PubMed
3) Rosenstock J, et al. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009 ; 11 : 571-8.
PubMed
4) Arechavaleta R, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy : a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011 ; 13 : 160-8.
PubMed
5) Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011 ; 13 : 193-203.
PubMed
P.195 掲載の参考文献
1) 中村昭伸ほか. 膵β細胞の保護から. 糖尿病診療 2010. 日医師会誌 2010 ; 139 特別号 (2) : S118-21.
 
2) Fukushima M, et al. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004 ; 66 (Suppl 1) : S37-43.
 
3) Nathan DM, et al. Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 ; 32 : 193-203.
 
4) 日本糖尿病学会編. 糖尿病治療ガイド 2010. 文光堂 ; 2010. p.29
 
5) Murry CE, et al. Preconditioning with ischemia : a delay of lethal cell injury in ischemic myocardium. Circulation 1986 ; 74 : 1124-36.
PubMed
6) Evans JM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 ; 330 : 1304-5.
PubMed
P.202 掲載の参考文献
1) Chiasson JL, et al. Acarbose for prevention of type 2 diabetes mellitus : the STOPNIDDM randomized trial. Lancet 2002 ; 359 : 2072-7.
PubMed
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
4) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
5) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
6) NAVIGATOR Study Group, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1463-76.
 
P.206 掲載の参考文献
1) Chiasson JL, et al. Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 2002 ; 359 : 2072-7.
PubMed
2) Kawamori R, et al. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 ; 373 : 1607-14.
PubMed
3) Mita T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biolo 2007 ; 27 : 2456-62.
 
4) Nishimura H, et al. Does Multiple Injection Therapy (MIT) with an Ultrarapid-Acting Insulin Analogue Prevent Cardiovascular Disease in Type 2 Diabetes? -The NICE-Study : A Prospective, Randomised, Open-Label, Blinded Endpoint Study. ADA 68th Scientific Sessions. 2008 ; Abstract Number : 163-OR.
 
5) Narita T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009 ; 26 : 187-8.
PubMed
6) Nonaka K, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 ; 79 : 291-8.
PubMed
7) Seino Y, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain : A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 ; 81 : 161-8.
 

9章 GLP - 1アナログ・GLP - 1受容体作動薬

P.213 掲載の参考文献
1) Nauck MA, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986 ; 63 : 492-8.
 
2) Nauck M, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 ; 29 : 46-52.
PubMed
3) 門脇孝ほか編. カラー版糖尿病学-基礎と臨床. 西村書店 ; 2007. pp.74-7.
 
4) Seino Y, et al. GIP and GLP-1, the two incretin hormones : Similarities and differences. J Diabetes Invest 2010 ; 1 : 8-23.
 
5) Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002 ; 122 : 531-44.
PubMed
6) Nauck MA, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993 ; 91 : 301-7.
 
7) Hojberg PV, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009 ; 52 : 199-207.
PubMed
P.217 掲載の参考文献
1) Chiasson JL, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 2003 ; 290 : 486-94.
PubMed
2) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
P.224 掲載の参考文献
1) Buse JB, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 ; 27 : 2628-35.
PubMed
2) DeFronzo RA, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 ; 28 : 1092-100.
PubMed
3) Kendall DM, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 ; 28 : 1083-91.
 
4) Zinman B, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes : a randomized trial. Ann Intern Med 2007 ; 146 : 477-85.
PubMed
5) Bergenstal RM, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2) : a randomized trial. Lancet 2010 ; 376 : 431-9.
PubMed
6) Nauck MA, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non-inferiority study. Diabetologia 2007 ; 50 : 259-67.
PubMed
7) Heine RJ, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes : a randomized trial. Ann Intern Med 2005 ; 143 : 559-69.
PubMed
8) Sheffield CA, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008 ; 14 : 285-92.
PubMed
9) Seino Y, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain : A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 ; 81 : 161-8.
 
10) Seino Y, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010 ; 26 : 1013-22.
PubMed
11) Kaku K, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010 ; 12 : 341-7.
PubMed
P.227 掲載の参考文献
1) Muller WA, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970 ; 283 : 109-15.
PubMed
2) Gromada J, et al. Alpha-cells of the endocrine pancreas : 35 years of research but the enigma remains. Endocr Rev 2007 ; 28 : 84-116.
PubMed
3) Reaven GM, et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987 ; 64 : 106-10.
 
4) Sorensen H, et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006 ; 55 : 2843-8.
PubMed
5) Kawamori D, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 2009 ; 9 : 350-61.
PubMed
6) Ishihara H, et al. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 2003 ; 5 : 330-5.
PubMed
7) Kolterman OG, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003 ; 88 : 3082-9.
PubMed
8) Ahren B, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 ; 89 : 2078-84.
PubMed
P.231 掲載の参考文献
1) Oliver-Krasinski JM, Stoffers DA. On the origin of the beta cell. Genes Dev 2008 ; 22 : 1998-2021.
PubMed
2) Dor Y, et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004 ; 429 : 41-6.
PubMed
3) Nir T, et al. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007 ; 117 : 2553-61.
PubMed
4) Inada A, et al. Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci U S A 2008 ; 105 : 19915-9.
PubMed
5) Solar M, et al. Pancreatic exocrine duct cells give rise to insulin-producing beta cells during embryogenesis but not after birth. Dev Cell 2009 ; 17 : 849-60.
 
6) Zhou J, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagonand insulin-producing cells. Diabetes 1999 ; 48 : 2358-66.
 
7) Hui H, et al. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001 ; 50 : 785-96.
PubMed
8) Hardikar AA, et al. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 2002 ; 143 : 3505-14.
PubMed
9) Abraham EJ, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002 ; 143 : 3152-61.
PubMed
10) Movassat J, et al. Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab 2002 ; 87 : 4775-81.
 
11) Zhou J, et al. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells : involvement of PDX-1 and HNF3beta transcription factors. J Cell Physiol 2002 ; 192 : 304-14.
PubMed
12) Stoffers DA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000 ; 49 : 741-8.
PubMed
13) Kodama S, et al. Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice. Biochem Biophys Res Commun 2005 ; 327 : 1170-8.
PubMed
14) Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007 ; 113 : 546-93.
PubMed
15) Buteau J, et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003 ; 52 : 124-32.
PubMed
16) Hui H, et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003 ; 144 : 1444-55.
 
17) Li Y, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003 ; 278 : 471-8.
PubMed
18) Buteau J, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004 ; 47 : 806-15.
PubMed
19) Park S, et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 2006 ; 281 : 1159-68.
PubMed
20) Jhala US, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003 ; 17 : 1575-80.
PubMed
21) Lingohr MK, et al. Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 2006 ; 281 : 15884-92.
 
22) Buteau J, et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001 ; 50 : 2237-43.
PubMed
23) Tuttle RL, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 2001 ; 7 : 1133-7.
PubMed
24) Bernal-Mizrachi E, et al. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 2001 ; 108 : 1631-8.
PubMed
25) Buteau J, et al. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006 ; 55 : 1190-6.
PubMed
26) Srinivasan S, et al. Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes 2005 ; 54 : 968-75.
PubMed
27) Liu Z, et al. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. Diabetologia 2008 ; 51 : 623-31.
PubMed
28) Tanabe K, et al. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol 2008 ; 6 : e37.
PubMed
29) Boucher MJ, et al. Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. J Biol Chem 2006 ; 281 : 6395-403.
PubMed
30) Mussmann R, et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007 ; 282 : 12030-7.
PubMed
31) Buteau J, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1) -cells. Diabetologia 1999 ; 42 : 856-64.
PubMed
32) Wang X, et al. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 1999 ; 140 : 4904-7.
PubMed
33) Li Y, et al. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005 ; 54 : 482-91.
PubMed
34) Wang H, et al. Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells. Diabetologia 2005 ; 48 : 720-31.
PubMed
35) Kahn SE, et al. The beta cell lesion in type 2 diabetes : there has to be a primary functional abnormality. Diabetologia 2009 ; 52 : 1003-12.
PubMed
36) Wang H, et al. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci 2005 ; 118 : 3905-15.
PubMed
37) Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 weekold db/db mice. Diabetologia 2002 ; 45 : 1263-73.
PubMed
38) Farilla L, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002 ; 143 : 4397-408.
PubMed
39) Farilla L, et al. Glucagon-like peptide-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003 ; 144 : 5149-58.
PubMed
40) Wang Q, et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004 ; 47 : 478-87.
PubMed
41) Buteau J, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004 ; 47 : 806-15.
PubMed
42) Yusta B, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006 ; 4 : 391-406.
PubMed
43) Tsunekawa S, et al. Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress ; in vivo and in vitro studies. J Endocrinol 2007 ; 193 : 65-74.
PubMed
44) Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008 ; 283 : 8723-35.
PubMed
45) Rulifson IC, et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 2007 ; 104 : 6247-52.
PubMed
46) O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature 2009 ; 462 : 307-14.
PubMed
47) Kim SJ, et al. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K) /protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005 ; 280 : 22297-307.
PubMed
48) Trumper A, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001 ; 15 : 1559-70.
PubMed
49) Trumper A, et al. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta (INS-1) -cells. J Endocrinol 2002 ; 174 : 233-46.
 
50) Ehses JA, et al. Glucose-dependent insulinotropic polypeptide promotes beta- (INS-1) cell survival via cyclic adenosine monophoshate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003 ; 144 : 4433-45.
 
51) Lynn FC, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001 ; 50 : 1004-11.
PubMed
52) Maida A, et al. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagonlike peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009 ; 137 : 2146-57.
PubMed
53) Mu J, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006 ; 55 : 1695-704.
 
54) Bunck MC, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients : a randomized, controlled trial. Diabetes Care 2009 ; 32 : 762-8.
PubMed
55) Scherbaum WA, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008 ; 10 : 1114-24.
PubMed
P.236 掲載の参考文献
1) Turton MD, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996 ; 379 : 69-72.
PubMed
2) Scrocchi LA, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996 ; 2 : 1254-8.
 
3) Wettergren A, et al. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998 ; 275 : G984-92.
PubMed
4) Vila PetroffMG, et al. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001 ; 89 : 445-52.
 
5) Gros R, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003 ; 144 : 2242-52.
PubMed
6) Zhao T, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006 ; 317 : 1106-13.
PubMed
7) Nikolaidis LA, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004 ; 109 : 962-5.
PubMed
8) Sokos GG, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006 ; 12 : 694-9.
PubMed
9) Yu M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003 ; 21 : 1125-35.
PubMed
10) Gutzwiller JP, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004 ; 89 : 3055-61.
 
11) Redondo A, et al. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003 ; 204 : 43-50.
PubMed
12) Ben-Shlomo S, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2010.
 
13) Miyawaki K, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002 ; 8 : 738-42.
PubMed
14) Tsukiyama K, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006 ; 20 : 1644-51.
PubMed
15) Zhong Q, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007 ; 292 : E543-8.
PubMed

10章 インスリン療法

P.243 掲載の参考文献
1) 内潟安子. 思春期・若年期糖尿病. 糖尿病 2004 ; 47 : 895-7.
 
2) 大谷敏嘉ほか. 50歳頃から重症低血糖と体重増加をきたした小児期発症1型糖尿病2症例の予後. 糖尿病 2009 ; 52 : 709-15.
 
3) 内潟安子. 月経周期とインスリン治療. Diabetes J 1999 ; 27 : 34-7.
 
4) 福島有香ほか. 糖尿病患者における血糖自己測定の有効な活用方法と病型による相違. 糖尿病 2001 ; 44 : 959-63.
 
P.252 掲載の参考文献
1) 小林正ほか. CoDiC(R) データ解析からみた糖尿病専門施設における治療実態 (2) -2型糖尿病におけるインスリン療法の現状と血糖コントロール状況について. 糖尿病診療マスター 2007 ; 5 : 401-6.
 
2) 難波光義. インスリン注射とGLP-1製剤. 糖尿病関連注射薬の新展開. フジメディカル出版 ; 2007. pp.8-15.
 
3) U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes : a progressive disease. U. K. Prospective Diabetes Study Group. Diabetes 1995 ; 44 : 1249-58.
 
4) 斎藤康ほか. DAWN JAPAN調査2005- (2) 2型糖尿病患者に対し, 適切な時期にインスリン治療が勧められているか? 糖尿病 2006 ; 49 (Supple 1) : S187.
 
5) Kosaka K, et al. Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 1977 ; 26 : 944-52.
PubMed
6) Kadowaki T, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984 ; 26 : 44-9.
PubMed
7) Mitsui R, et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism 2006 ; 55 : 53-8.
PubMed
8) 勝野朋幸ほか. 診療controversy - medical decision makingのために2型糖尿病患者に対するインスリン導入-まず1日1回注射から. 臨床雑誌内科 2010 ; 106 : 133-8.
 
9) Chaudhuri A, et al. The combination of insulin and metformin in treatment of non-insulin-dependent diabetes mellitus. Endocr Pract 1998 ; 4 : 259-67.
PubMed
10) Aviles-Santa L, et al. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999 ; 131 : 182-8.
PubMed
11) 後藤広昌ほか. 2型糖尿病のスルホニル尿素薬効果不十分例におけるインスリングラルギンの上乗せ効果-18ヵ月間の長期治療効果の検討. 糖尿病 2007 ; 50 : 591-7.
 
12) 難波光義ほか. 日本人2型糖尿病患者におけるインスリン治療の導入-全国医療機関へのアンケート調査結果の分析. Diabetes Frontier 2009 ; 20 : 491-7.
Medical*Online
13) Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998 ; 21 : 1052-7.
PubMed
14) Shank ML, et al. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995 ; 44 : 165-72.
PubMed
15) Johnson JL, et al. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996 ; 156 : 259-64.
PubMed
16) United Kingdom Prospective Diabetes Study 24 : a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998 ; 128 : 165-75.
PubMed
17) Alberti G. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1998-1999 International Diabetes Federation European Region. Exp Clin Endocrinol Diabetes 1999 ; 107 : 390-420.
PubMed
18) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン, 改訂第2版. 南江堂 ; 2007. pp.55-65.
 
19) Janka HU, et al. Comparison of basal insulin added to oral agents versus twicedaily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005 ; 28 : 254-9.
PubMed
20) Holman RR, et al ; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007 ; 357 : 1716-30.
PubMed
21) Bretzel RG, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO) : an open randomized controlled trial. Lancet 2008 ; 371 : 1073-84.
PubMed
22) 三谷康二ほか. High-mix 混合型インスリンアナログ製剤 (ノボラピッド(R) 70ミックス) 1日3回注射法の臨床的有用性. 新薬と臨床 2010 ; 59 : 122-30.
 
P.260 掲載の参考文献
1) Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins : impact on efficacy and safety. Am J Med 2008 ; 121 (6 Suppl) : S9-19.
 
2) Heise T, et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart : a randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008 ; 10 : 479-85.
PubMed
3) 石井均ほか. 1日2回投与法によるリスプロ混合製剤-25およびリスプロ混合製剤-50の1型および2型糖尿病患者のQOLに与える影響. 糖尿病 2005 ; 48 : 607-16.
 
4) Jang HC, et al ; PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008 ; 62 : 1013-8.
 
5) Liebl A, et al ; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study : a randomized controlled trial. Diabetes Obes Metab 2009 ; 11 : 45-52.
 
6) Masuda H, et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy : glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. Diabetes Obes Metab 2008 ; 10 : 1261-5.
PubMed
7) Rosenstock J, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008 ; 31 : 20-5.
PubMed
8) Kalra S, et al. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract 2010 ; 88 : 282-8.
PubMed
9) Strojek K, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs : an open-label, multinational RCT. Curr Med Res Opin 2009 ; 25 : 2887-94.
PubMed
10) Garber AJ, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006 ; 8 : 58-66.
PubMed
11) Cucinotta D, et al. Three different premixed combinations of biphasic insulin aspart-comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab 2009 ; 11 : 700-8.
 
12) Ishii H, et al. Improvement of glycemic control and quality-of-life by insulin lispro therapy : Assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract 2008 ; 81 : 169-78.
PubMed
P.266 掲載の参考文献
1) 日本糖尿病学会編. 糖尿病学用語集. 第3版. 文光堂 ; 2011.
 
2) Hirao K, et al. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008 ; 79 : 171-6.
PubMed
3) Miyashita Y, et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008 ; 7 : 16.
PubMed
4) Masuda H, et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy : glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. Diabetes Obes Metab 2008 ; 10 : 1261-5.
PubMed
5) Rosenstock J, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008 ; 31 : 20-5.
PubMed
6) Holman RR, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009 ; 361 : 1736-47.
PubMed
7) Rossetti P, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime : a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003 ; 26 : 1490-6.
PubMed
8) Albright ES, et al. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004 ; 27 : 632-3.
PubMed
9) Porcellati F, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004 ; 21 : 1213-20.
PubMed
10) Ratner RE, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000 ; 23 : 639-43.
 
11) Porcellati F, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004 ; 21 : 1213-20.
PubMed
12) Tamaki M, et al. Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). Diabetes Res Clin Pract 2008 ; 81 : e1-3.
 
P.272 掲載の参考文献
1) 吉岡成人. 心理行動を考慮したインスリン治療の進め方. 診断と治療 2009 ; 97 : 306-9.
Medical*Online
2) Labovitz HE. In : Kahn CR. Joslin's Diabetes Mellitus. 14th ed. Lippincott Williams & Willkins ; 2005. pp.687-710.
 
3) Weng J, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes : a multicentre randomized parallel-group trial. Lancet 2008 ; 371 : 1753-60.
 
4) Holman RR, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007 ; 357 : 1716-30.
 
5) Janka HU, et al. Comparison of basal insulin added to oral agents versus twicedaily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005 ; 28 : 254-9.
PubMed
6) Rosenstock J, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008 ; 51 : 408-16.
PubMed
7) Narita T, et al. Efficacy and safety of patient-directed titration of once-daily predinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drugfailure : STEP-AKITA study. J Diabetes Invest 2011 ; 2 : 63-70.
 
8) Ebato C, et al. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30) : comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with submaximal glimepiride. Diabetes Res Clin Pract 2009 ; 86 : 31-6.
PubMed
9) 後藤広昌ほか. 2型糖尿病のスルホニル尿素薬効果不十分例におけるインスリングラルギンの上乗せ効果-18ヵ月間の長期治療効果の検討. 糖尿病 2007 ; 50 : 591-7.
 
10) 岡本かへでほか. 2型糖尿病のSU 薬とグラルギン併用療法効果不十分例における超速効型インスリンの段階的追加法の検討 (JUN-LAN Study 7). 糖尿病 2009 ; 52 : 197-202.
 
11) Yoshioka N, et al. Step-up therapy with biphasic insulin aspart-70/30-Sapporo 1-2-3 study. Diabetes Res Clin Pract 2009 ; 85 : 47-52.
PubMed
P.281 掲載の参考文献
1) 浜口朋也, 難波光義. インスリン持続皮下注入療法 (CSII) -その有用性と課題. 医学のあゆみ 2007 ; 220 : 1239-43.
Medical*Online
2) 浜口朋也, 難波光義. インスリンポンプ療法の今後. 小林哲郎, 難波光義編. インスリンポンプ療法マニュアル-CSII療法導入・管理のための手引き, 南江堂 ; 2009, pp.161-5.
 
3) Fatourechi MM, et al. Clinical review : Hypoglycemia with intensive insulin therapy : a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009 ; 94 : 729-40.
PubMed
4) Castera V, et al. Systemic allergy to human insulin and its rapid and long acting analogs : successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005 ; 31 : 391-400.
PubMed
5) Yates K, et al. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens : a randomized controlled trial. Diabetes Care 2006 ; 29 : 1512-7.
PubMed
6) Hovorka R, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes : crossover randomised controlled studies. BMJ 2011 ; 342. (on line, 14 April 2011)
 
7) Guerci B, et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999 ; 84 : 2673-8.
PubMed
P.288 掲載の参考文献
1) Kawasaki E, et al. Type 1 diabetes in Japan. Diabetologia 2006 ; 49 : 828-36.
PubMed
2) Horie I, et al. Emergence of anti-islet autoantibodies in Japanese patients with type 1 diabetes. Endocr J 2010 ; 57 : 623-8.
PubMed
3) Kawasaki E, et al. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab. 2010 ; 95 : 707-13.
PubMed
4) Steffes MW, et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003 ; 26 : 832-6.
PubMed
5) Thunander M, et al. β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment : a 3-year follow-up. Eur J Endocrinol 2011 ; 164 : 239-45.
 
6) Yang Z, et al. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 2009 ; 83 : 54-60.
PubMed

11章 小児糖尿病, 糖尿病妊婦, 高齢糖尿病患者の治療

P.296 掲載の参考文献
1) Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus : Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994 ; 125 : 177-88.
 
2) White NH, et al ; Diabetes Control and Complications Trial (DCCT) / Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence : outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001 ; 139 : 804-12.
 
3) Rewers M, et al ; International Society for Pediatric and Adolescent Diabetes (ISBAD). ISPAD Clinical Practice Consensus Guidelines 2006-2008 Compendium Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2007 ; 8 : 408-18. (国際小児思春期糖尿病学会編. 臨床診療コンセンサスガイドライン2006-2008. ガイドライン全体の翻訳は日本小児内分泌学会のホームページのガイドライン ; http://jspe.umin.jp/)
 
4) 日本糖尿病学会・日本小児内分泌学会編. 小児・思春期糖尿病管理の手びき. 改訂第3版-コンセンサス・ガイドライン. 南江堂 ; 2011.
 
5) 厚生労働省「日本人の食事摂取基準」策定検討会報告書. 日本人の食事摂取基準. 2010年度版. 第一出版 ; 2009. p.61.
 
6) 雨宮伸. メタボリックシンドローム-A. 肥満の生理学. 日本小児内分泌学会編. 小児内分泌学. 診断と治療社 ; 2009. pp.497-50.
 
7) 日本肥満学会編. 肥満症治療ガイドライン 2006.
 
8) 坂田利家編. 肥満症治療マニュアル. 医歯薬出版 ; 1996.
 
9) 松浦信夫ほか. 小児2型糖尿病に対するメトホルミン単独療法. 糖尿病 2008 ; 51 : 427-34.
 
10) Rosenbloom AL, et al ; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2006?2007. Type 2 diabetes mellitus in the child and adolescent. Pediatr Diabetes 2008 ; 9 : 512-26.
PubMed
11) Sugihara S, et al. Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan. Clin Pediatr Endocrinol 2005 ; 14 : 65-75.
PubMed
12) Levy-Marchal C, et al. Insulin resistance in children : consensus, perspective, and future directions. J Clin Endocrinol Metab 2010 ; 95 : 5189-98.
PubMed
P.304 掲載の参考文献
1) American Diabetes Association. Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 2009 ; 32 (Suppl 1) : S62-7.
 
2) Shimizu I, et al. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 2006 ; 91 : 471-6.
PubMed
3) Omori Y, Javonovic L. Proposal for the reconsideration of the definition of gestational diabetes. Diabetes Care 2005 ; 28 : 2592-3.
 
4) International Association of Diabetes and Pregnancy Study Groups Consensus Panel, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010 ; 33 : 676-82.
PubMed
5) Shimizu I, et al. 2-hour glucose > 200 mg/dl on 75 g OGTT is associated with the early development of type 2 diabetes in Japanese women with GDM. International Workshop Conference on Gestational Diabetes Pasadena 2. (abstract)
 
6) 中林正雄ほか. 妊娠糖尿病診断基準検討委員会. 妊娠糖尿病診断基準変更に関する委員会報告. 糖尿病と妊娠 2010 ; 10 : 21.
 
7) 日本産科婦人科学会, 日本産婦人科医会編. 妊婦の耐糖能検査は? 産婦人科診療ガイドライン-産科編 2008. 日本産科婦人科学会 ; 2008. pp.13-6.
 
8) 増本由美ほか. 新しい妊娠糖尿病診断基準採用による妊娠糖尿病の頻度と周産期予後への影響. 糖尿病と妊娠 2010 ; 10 : 88-91.
 
9) 平松祐司ほか. 正常妊婦におけるグリコアルブミン, ヘモグロビンA1cの基準範囲の設定. 糖尿病と妊娠 2010 ; 10 : 22-6.
 
10) 清水一紀ほか. 糖尿病合併妊婦および妊娠糖尿病におけるグリコアルブミンと母児合併症に関する調査. 糖尿病と妊娠 2010 ; 10 : 27-31.
 
P.309 掲載の参考文献
1) Basu R, et al. Mechanisms of the age-associated deterioration in glucose tolerance : contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003 ; 52 : 1738-48.
PubMed
2) 佐藤祐造編. 高齢者運動処方ガイドライン. 南江堂 ; 2002.
 
3) 横野浩一. 高齢者糖尿病の臨床. 日本老年医学会雑誌 2007 ; 44 : 572-4.
 

12章 高血糖緊急症の診断と治療

P.318 掲載の参考文献
1) Kirkman MS, Juneja R. Misleading algorithm for management of adult patients with diabetic ketoacidosis. Diabetes Care 2001 ; 24 : 2009-11.
PubMed
2) 小林正編. インスリン療法マニュアル. 第4版. 文光堂 ; 2008.
 
3) 野中共平. 糖尿病臨床閑話-第2回ソフトドリンク・ケトーシス-日本社会の歪みを具現. 臨床と研究 2010 ; 87 : 1180-1.
Medical*Online
4) 尾渕美弥子. ケトン体 (血中・尿中). 糖尿病ケア 2010 ; 7 : 22-6.
Medical*Online
P.323 掲載の参考文献
1) Kitabchi AE, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009 ; 32 : 1335-43.
PubMed
2) 日本糖尿病学会編. 糖尿病専門医研修ガイドブック. 改訂第4版. 診断と治療社 ; 2009.
 
・ Scott A. Hyperosmolar hyperglycaemic syndrome. Diabet Med 2006 ; 23 (Suppl 3) : 22-4.
 

13章 シックデイと低血糖

P.329 掲載の参考文献
1) Laffel L, et al. Treatment of the child and adolescent with diabetes. In : Kahn CR, et al. eds. Joslin's Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins ; 2005. pp. 711-36.
 
2) Skyler JS, et al. Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. Diabetes Care 1981 ; 4 : 311-8.
PubMed
P.333 掲載の参考文献
1) Monami M, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006 ; 22 : 477-82.
PubMed
2) Gangji AS, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events : a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007 ; 30 : 389-94.
PubMed
3) Simpson SH, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus : a population-based cohort study. CMAJ 2006 ; 174 : 169-74.
PubMed
4) Mannucci E, et al. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004 ; 20 : 44-7.
PubMed
5) Fisman EZ, et al. Oral antidiabetic treatment in patients with coronary disease : time-related increased mortality on combined glyburide/metformin therapy over 7. 7-year follow-up. Clin Cardiol 2001 ; 24 : 151-8.
PubMed
6) Frier BM. Cognitive functioning in type 1 diabetes : the Diabetes Control and Complications Trial (DCCT) revisited. Diabetologia 2011 ; 54 : 233-6.
PubMed
7) Whitmer RA, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009 ; 301 : 1565-72.
PubMed
8) Turchin A, et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009 ; 32 : 1153-7.
PubMed
9) Kosiborod M, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009 ; 301 : 1556-64.
PubMed
10) American Diabetes Association. Clinical Practice Recommendations. Diabetes Care 2011 ; 34 (Suppl 1).
 
11) Currie CJ, et al. Survival as a function of HbA (1c) in people with type 2 diabetes : a retrospective cohort study. Lancet 2010 ; 375 : 481-9.
PubMed
12) 松田昌文. 病棟血糖管理マニュアル-理論と実践. 増補版. 金原出版 ; 2010.
 

14章 糖尿病治療における教育

P.339 掲載の参考文献
1) 松岡健平. 変貌する糖尿病療養指導士の役割. CDEJ News Letter 5号 2004年11月.
 
2) 山本美砂子. 糖尿病療養指導士の養成-アメリカにおける糖尿病療養指導士 (CDE) の成り立ちと現状. プラクティス 1998 ; 15 : 264-7.
 
3) 日本糖尿病療養指導士認定機構編. 糖尿病療養指導ガイドブック 2011. メディカルレビュー社 ; 2011.
 
4) 武田純. 療養指導委員会-糖尿病治療の質的向上と制度化を図る. 日本糖尿病協会50周年記念事業委員会編. 50年のあゆみ-希望の未来へ. 日本糖尿病協会 ; 2011. p.60.
 
5) 伴野祥一. 糖尿病療養指導士とチーム医療. Pharma Medica 2007 ; 25 : 35-8.
Medical*Online
P.344 掲載の参考文献
1) 日本糖尿病学会編. 糖尿病治療ガイド 2010. 文光堂 ; 2010
 

書評

最近チェックした商品履歴

Loading...